Back to Trades
Total Value
$28.0K
Net $28.0K sold
Filing Date
Aug 29, 2025
2 transactions
Sales
$28.0K
2 transactions
Trade Summary
On Aug 27, 2025 through Aug 28, 2025, Szot Matthew K, Chief Financial Officer, sold $28.0K of Cadrenal Therapeutics, Inc. (CVKD) across 2 transactions. The filing covers Common Stock and reflects net selling of $28.0K. Reported prices ranged from $13.99. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Cadrenal Therapeutics, Inc.
- Ticker Symbol
- CVKD
- CIK
- 0001937993
Insider Information
- Name
- Szot Matthew K
- Role
- Chief Financial Officer
- Location
- PONTE VEDRA, FL
Filing Details
- Filing Date
- Aug 29, 2025
- Transaction Date
- Aug 27, 2025
- Accession Number
- 0001213900-25-082821
- Form Type
- 4
- Net Trading Amount
- -$28.0K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Aug 27, 2025 | Common Stock | 1,600 | $13.99 | Sale | $22.4K |
| Aug 28, 2025 | Common Stock | 400 | $14.00 | Sale | $5.6K |
Want live alerts when Szot Matthew K trades again?
Download Insider Trades to track CVKD, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions, each at $14.000. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.